Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Dimethyl fumarate (Primary) ; Daclizumab; Peginterferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TEC-GISTRY
- Sponsors Biogen
- 09 Feb 2017 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2028.
- 27 Jan 2017 Planned End Date changed from 1 Dec 2023 to 1 Jun 2028.
- 19 May 2016 The number of treatment arms have been amended from 2 to 3. An additional dalclizumab arm has been added to the treatments.